SPTY2D1

Across TCGA pan-cancer cohorts, SPTY2D1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPTY2D1 data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SPTY2D1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPTY2D1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where SPTY2D1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.514	0.816	.011	19	view →
LUAD	DFS	Median	II,III,IV	0.922	0.784	.003	11	view →
UCEC	DFS	Median	All	0.788	0.919	.046	2	view →
GBM	OS	Quartile	All	0.833	0.995	.011	2	view →
LSCC	DFS	Quartile	II,III,IV	0.198	0.887	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPTY2D1–CCRCC (DFS)

Open the CCRCC breakdown →